Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease
MD, MSc Jihad Mallat, MD Fadi Hamed, MD Maher Balkis, MD e , Mohamed A Mohamed, MD d Mohamad Mooty, MD Asim Malik, MD d , Ahmad Nusair, MD Maria-Fernanda Bonilla
Medicine, doi:10.1097/md.0000000000023720
There are conflicting data regarding the use of hydroxychloroquine (HCQ) in COVID-19 hospitalized patients. The objective of this study was to assess the efficacy of HCQ in increasing SARS-CoV-2 viral clearance. Hospitalized adult patients with confirmed SARS-CoV-2 infection were retrospectively included in the study. The primary outcome was the time from a confirmed positive nasopharyngeal swab to turn negative. A negative nasopharyngeal swab conversion was defined as a confirmed SARS-CoV-2 case followed by 2 negative results using RT-PCR assay with samples obtained 24 hours apart. Multiple linear regression analysis was used to adjust for potential confounders. Thirty-four confirmed COVID-19 patients completed the study. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received HCQ. The time to SARS-CoV-2 negativity nasopharyngeal test was significantly longer in patients who received HCQ than those who did not receive HCQ [17 (13-21) vs 10 (4-13) days, P = .023]. HCQ was independently associated with time to negativity test after adjustment for potential confounders (symptoms, comorbidities, antiviral drugs, pneumonia, or oxygen therapy) in multivariable Cox proportional hazards regression analysis (hazard ratio = 0.33, 95% confidence interval: 0.13-0.9, P = .024). On day 14, 47.8% (14/23) patients tested negative in the HCQ group compared with 90.9% (10/11) patients who did not receive HCQ (P = .016). HCQ was associated with a slower viral clearance in COVID-19 patients with mild to moderate disease. Data from ongoing randomized clinical trials with HCQ should provide a definitive answer regarding the efficacy and safety of this treatment. Abbreviations: HCQ = hydroxychloroquine, RT-PCR = real-time reverse-transcriptase-polymerase chain reaction.
Author contributions Mallat had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
References
Chen, Liu, Liu, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19, COVID
Devaux, Rolain, Colson, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents
Efron, Tibshirani, Better confidence intervals
Ferritin, None, reference range
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Hcq, Mallat, = hydroxychloroquine, Medicine
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Maa, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacol Res Perspect
Maheshwari, Srikantan, Bhartiya, Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice, J Virol
Mallat, None, Medicine
Molina, Delaugerre, Goff, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect
Paton, Goodall, Dunn, Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial, JAMA
Ponticelli, Moroni, Hydroxychloroquine in systemic lupus erythematosus (SLE), Expert Opin Drug Saf
Roques, Thiberville, Dupuis-Maguiraga, Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection, Viruses
Schrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol
Seth, Mani, Singh, Acceleration of viral replication and upregulation of cytokine levels by antimalarials: implications in malariaendemic areas, Am J Trop Med Hyg
Tang, Cao, Han, Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, medRxiv
Touret, De Lamballerie, Of chloroquine and COVID-19, Antiviral Res
Who, Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance
Wilson, Chotirmall, Bai, COVID-19: Interim Guidance on Management Pending Empirical Evidence
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhejiang, None, Med Sci
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
